111317-91-0 Usage
Description
CONOPRESSIN G is a synthetic analog of vasopressin, a hormone that plays a crucial role in regulating water balance in the body. As a vasopressin receptor agonist, it activates the vasopressin receptors, thereby mimicking the effects of the natural hormone. Although not yet approved for clinical use in humans, CONOPRESSIN G is extensively utilized in medical research to explore the impacts of vasopressin on various physiological processes, including blood pressure regulation, kidney function, and fluid balance.
Uses
Used in Medical Research:
CONOPRESSIN G is used as a research tool for studying the effects of vasopressin on physiological processes such as blood pressure regulation, kidney function, and fluid balance. It aids in understanding the intricate mechanisms of these processes and the role of vasopressin in maintaining homeostasis.
Used in Animal Studies:
In the field of veterinary medicine, CONOPRESSIN G is used as a therapeutic agent in animal studies to investigate its potential effects on conditions like diabetes insipidus, hypotension, and septic shock. These studies provide valuable insights into the possible applications of CONOPRESSIN G in treating similar conditions in humans.
While CONOPRESSIN G is not currently approved for clinical use in humans, ongoing research continues to explore its potential therapeutic applications. The findings from these studies could pave the way for new treatments and therapeutic strategies in the future.
Check Digit Verification of cas no
The CAS Registry Mumber 111317-91-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,1,3,1 and 7 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 111317-91:
(8*1)+(7*1)+(6*1)+(5*3)+(4*1)+(3*7)+(2*9)+(1*1)=80
80 % 10 = 0
So 111317-91-0 is a valid CAS Registry Number.
InChI:InChI=1/C44H71N15O10S2/c1-3-24(2)35-42(68)54-28(14-9-17-51-44(49)50)38(64)56-30(20-33(47)60)39(65)57-31(23-71-70-22-26(46)36(62)55-29(40(66)58-35)19-25-11-5-4-6-12-25)43(69)59-18-10-15-32(59)41(67)53-27(13-7-8-16-45)37(63)52-21-34(48)61/h4-6,11-12,24,26-32,35H,3,7-10,13-23,45-46H2,1-2H3,(H2,47,60)(H2,48,61)(H,52,63)(H,53,67)(H,54,68)(H,55,62)(H,56,64)(H,57,65)(H,58,66)(H4,49,50,51)/t24-,26-,27-,28-,29-,30-,31-,32-,35?/m0/s1
111317-91-0Relevant articles and documents
Exploiting the MeDbz Linker To Generate Protected or Unprotected C-Terminally Modified Peptides
Arbour, Christine A.,Saraha, Hasina Y.,McMillan, Timothy F.,Stockdill, Jennifer L.
, p. 12484 - 12488 (2017)
C-terminally modified peptides are important targets for pharmaceutical and biochemical applications. Known methods for C-terminal diversification are limited mainly in terms of the scope of accessible modifications or by epimerization of the C-terminal amino acid. In this work, we present a broadly applicable approach that enables access to a variety of C-terminally functionalized peptides in either protected or unprotected form. This chemistry proceeds without epimerization of C-terminal Ala and tolerates nucleophiles of varying nucleophilicity. Finally, unprotected peptides bearing nucleophilic side chain groups can be selectively functionalized by strong nucleophiles, whereas macrocyclization is observed for weaker nucleophiles. The potential utility of this method is demonstrated through the divergent synthesis of the conotoxin conopressin G and GLP-1(7-36) and analogs.